Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.

Ceramides increase during obesity and promote insulin resistance. Ceramides vary in acyl-chain lengths from C14:0 to C30:0 and are synthesized by six ceramide synthase enzymes (CerS1-6). It remains unresolved whether obesity-associated alterations of specific CerSs and their defined acyl-chain length ceramides contribute to the manifestation of metabolic diseases. Here we reveal that CERS6 mRNA expression and C16:0 ceramides are elevated in adipose tissue of obese humans, and increased CERS6 expression correlates with insulin resistance. Conversely, CerS6-deficient (CerS6(Δ/Δ)) mice exhibit reduced C16:0 ceramides and are protected from high-fat-diet-induced obesity and glucose intolerance. CerS6 deletion increases energy expenditure and improves glucose tolerance, not only in CerS6(Δ/Δ) mice, but also in brown adipose tissue- (CerS6(ΔBAT)) and liver-specific (CerS6(ΔLIVER)) CerS6 knockout mice. CerS6 deficiency increases lipid utilization in BAT and liver. These experiments highlight CerS6 inhibition as a specific approach for the treatment of obesity and type 2 diabetes mellitus, circumventing the side effects of global ceramide synthesis inhibition.

[1]  J. Górski,et al.  Increased Bioactive Lipids Content in Human Subcutaneous and Epicardial Fat Tissue Correlates with Insulin Resistance , 2012, Lipids.

[2]  K. Matsuda,et al.  A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity , 2013, Nature.

[3]  Oliver T. Bruns,et al.  Brown adipose tissue activity controls triglyceride clearance , 2011, Nature Medicine.

[4]  M. Hallek,et al.  B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. , 2012, Blood.

[5]  M. Lorenzo,et al.  Ceramide mediates TNF-alpha-induced insulin resistance on GLUT4 gene expression in brown adipocytes. , 2006, Archives of physiology and biochemistry.

[6]  M. Orešič,et al.  Comparison of Lipid and Fatty Acid Composition of the Liver, Subcutaneous and Intra‐abdominal Adipose Tissue, and Serum , 2010, Obesity.

[7]  Jacek Bielawski,et al.  Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. , 2009, American journal of physiology. Endocrinology and metabolism.

[8]  M. Birnbaum,et al.  Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. , 2007, Cell metabolism.

[9]  V. Menuz,et al.  Protection of C. elegans from Anoxia by HYL-2 Ceramide Synthase , 2009, Science.

[10]  C. Kellendonk,et al.  Hepatocyte‐specific expression of Cre recombinase , 2000, Genesis.

[11]  P. Scherer,et al.  An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. , 2013, Cell metabolism.

[12]  E. Abel,et al.  Ceramide Mediates Vascular Dysfunction in Diet-Induced Obesity by PP2A-Mediated Dephosphorylation of the eNOS-Akt Complex , 2012, Diabetes.

[13]  Liana C. Silva,et al.  A Critical Role for Ceramide Synthase 2 in Liver Homeostasis , 2010, The Journal of Biological Chemistry.

[14]  D. Muoio,et al.  Inhibition of De Novo Ceramide Synthesis Reverses Diet-Induced Insulin Resistance and Enhances Whole-Body Oxygen Consumption , 2010, Diabetes.

[15]  Mammalian ceramide synthases , 2010, IUBMB life.

[16]  S. Summers,et al.  A ceramide-centric view of insulin resistance. , 2012, Cell metabolism.

[17]  P. Froguel,et al.  Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions , 2007, Nature Medicine.

[18]  J. Degen,et al.  Ablation of Neuronal Ceramide Synthase 1 in Mice Decreases Ganglioside Levels and Expression of Myelin-associated Glycoprotein in Oligodendrocytes* , 2012, The Journal of Biological Chemistry.

[19]  Y. Igarashi,et al.  Ceramide kinase deficiency improves diet‐induced obesity and insulin resistance , 2012, FEBS letters.

[20]  D. O'sullivan,et al.  1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. , 1990, The Journal of biological chemistry.

[21]  D. Langin,et al.  Adipocyte lipases and lipid droplet-associated proteins: insight from transgenic mouse models , 2012, International Journal of Obesity.

[22]  D. Ory,et al.  Palmitate and Lipopolysaccharide Trigger Synergistic Ceramide Production in Primary Macrophages* , 2012, The Journal of Biological Chemistry.

[23]  S. Summers,et al.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. , 2008, Endocrine reviews.

[24]  P. Meikle,et al.  Ceramides Contained in LDL Are Elevated in Type 2 Diabetes and Promote Inflammation and Skeletal Muscle Insulin Resistance , 2013, Diabetes.

[25]  K. Willecke,et al.  Loss of ceramide synthase 3 causes lethal skin barrier disruption. , 2012, Human molecular genetics.

[26]  A. Scherz,et al.  Ablation of Ceramide Synthase 2 Causes Chronic Oxidative Stress Due to Disruption of the Mitochondrial Respiratory Chain* , 2013, The Journal of Biological Chemistry.

[27]  A. Häkkinen,et al.  Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects With High Liver Fat Content Independent of Obesity , 2007, Diabetes.

[28]  R. DeFronzo,et al.  Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. , 2004, Diabetes.

[29]  M. Lorenzo,et al.  Ceramide mediates TNF-α-induced insulin resistance on GLUT4 gene expression in brown adipocytes , 2006 .

[30]  S. Summers,et al.  CerS2 Haploinsufficiency Inhibits β-Oxidation and Confers Susceptibility to Diet-Induced Steatohepatitis and Insulin Resistance. , 2014, Cell metabolism.

[31]  M. Birnbaum,et al.  Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin , 2011, Nature Medicine.